A carregar...
Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy, which is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), can be associated with potentially severe and costly neurologic adverse events (AEs). OBJECTIVES: To develop an evidence-based list of trea...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7741176/ https://ncbi.nlm.nih.gov/pubmed/33343819 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|